GlassScriptPhysician profile
Nathan B Adams
NPI 1891857512
$15,913.96
in general payments reported to CMS, 2019-2025
73 companies · $2,803 in 2025
The $2,803 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,410 · 2020: $1,635 · 2021: $1,909 · 2022: $2,685 · 2023: $2,280 · 2024: $2,193 · 2025: $2,803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,311 · Education: $666 · Long Term Medical Supply Or Device Loan: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,311.45 |
| Education | $665.70 |
| Long Term Medical Supply Or Device Loan | $299.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,637.24 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Novartis Pharmaceuticals Corporation | $1,499.38 | 2019-2025 | |
| Pfizer INC. | $1,397.48 | 2019-2025 | |
| Amgen INC. | $791.20 | 2019-2023 | Lumakras, Blincyto, Kyprolis |
| Astellas Pharma US INC | $780.93 | 2019-2025 | Padcev, Xtandi, Vyloy |
| Astrazeneca Pharmaceuticals LP | $732.23 | 2019-2025 | Lynparza, Imfinzi, Calquence |
| Genentech USA, INC. | $622.94 | 2019-2025 | Phesgo, Perjeta, Alecensa |
| Celgene Corporation | $577.34 | 2019-2025 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $536.84 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $511.10 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Janssen Biotech, INC. | $505.88 | 2019-2025 | Rybrevant, Erleada, Akeega |
| Seagen INC. | $470.80 | 2020-2025 | Adcetris |
| Abbvie INC. | $458.39 | 2019-2025 | Venclexta |
| Eisai INC. | $391.96 | 2019-2025 | |
| Genzyme Corporation | $375.16 | 2020-2025 |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $302.75 | 2019-2023 | Imbruvica |
| Aveo Pharmaceuticals, INC. | $283.45 | 2023-2025 | Fotivda |
| Bayer Healthcare Pharmaceuticals INC. | $281.79 | 2019-2025 | |
| Emd Serono, INC. | $273.98 | 2019-2024 | Bavencio |
| Glaxosmithkline, LLC. | $243.75 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Gilead Sciences, INC. | $236.76 | 2019-2025 | Trodelvy |
| Incyte Corporation | $175.23 | 2019-2024 | Jakafi, Monjuvi |
| Sobi, INC | $169.46 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $149.71 | 2019-2025 | Fruzaqla, Ninlaro |
| Puma Biotechnology, INC. | $148.66 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.69 | 2019-2025 | Gilotrif |
| Jazz Pharmaceuticals INC. | $139.13 | 2020-2025 | |
| Beigene USA, INC. | $114.34 | 2020-2025 | Brukinsa |
| Beone Medicines USA, INC. | $113.20 | 2025 | Brukinsa, Tevimbra |
| Rigel Pharmaceuticals, INC. | $109.94 | 2019-2024 | Tavalisse, Rezlidhia |
| Dendreon Pharmaceuticals LLC | $107.65 | 2019-2025 | Provenge |
| Exelixis INC. | $107.25 | 2019-2024 | Cabometyx |
| Lilly USA, LLC | $103.15 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Sanofi-Aventis U.S. LLC | $99.99 | 2020 | |
| Servier Pharmaceuticals LLC | $95.40 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $72.19 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $71.74 | 2023-2025 | Orgovyx |
| Tersera Therapeutics LLC | $71.59 | 2021-2025 | Zoladex, Xermelo |
| Kite Pharma, INC. | $65.09 | 2022-2023 | Yescarta |
| Myovant Sciences INC. | $62.53 | 2021-2022 | |
| Iovance Biotherapeutics, INC. | $55.61 | 2025 | Amtagvi |
| Adaptive Biotechnologies Corporation | $52.67 | 2022-2025 | Clonoseq |
| Sirtex Medical INC | $48.77 | 2019-2022 | |
| Cti Biopharma Corp. | $44.38 | 2022-2023 | Vonjo |
| Medtronic, INC. | $39.81 | 2022-2025 | Synchromedii |
| Ipsen Biopharmaceuticals, INC | $36.53 | 2019-2020 | |
| Springworks Therapeutics, INC. | $36.39 | 2024-2025 | Ogsiveo |
| Blueprint Medicines Corporation | $35.37 | 2024 | Ayvakit |
| Agios Pharmaceuticals, INC. | $33.14 | 2019-2020 | |
| Karyopharm Therapeutics INC. | $32.19 | 2020-2024 | Xpovio |
| Alexion Pharmaceuticals, INC. | $28.64 | 2019-2021 | |
| Pharmacosmos Therapeutics INC. | $28.25 | 2023 | Monoferric |
| Boston Scientific Corporation | $27.26 | 2023 | Watchman Flx |
| Organon LLC | $25.79 | 2021-2022 | |
| Geron Corporation | $24.90 | 2025 | Rytelo |
| Eusa Pharma (US) LLC | $23.58 | 2021-2022 | |
| Pharmaessentia USA Corporation | $22.99 | 2024 | Besremi |
| Novocure INC. | $22.29 | 2025 | Optune Lua (Novottf-200t) |
| Array Biopharma INC | $21.77 | 2023-2025 | Xalkori, Lorbrena, Braftovi |
| Syndax Pharmaceuticals, INC. | $21.67 | 2025 | Revuforj |
| Deciphera Pharmaceuticals INC. | $20.17 | 2023 | Qinlock |
| Verastem, INC. | $19.68 | 2019 | |
| Adc Therapeutics America, INC. | $19.52 | 2025 | |
| Morphosys, US INC. | $18.27 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $17.95 | 2019 | |
| Mirati Therapeutics, INC. | $17.55 | 2023 | Krazati |
| Genmab U.S., INC. | $17.55 | 2023 | Epkinly |
| Spectrum Pharmaceuticals INC. | $17.11 | 2024 | Rolvedon |
| Aurobindo Pharma USA, INC. | $15.67 | 2019 | |
| Secura Bio, INC. | $14.91 | 2020 | |
| Clovis Oncology, INC. | $13.95 | 2019 | |
| Acrotech Biopharma INC. | $13.93 | 2021 | |
| Taiho Oncology, INC. | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.